KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Non-Current Liabilities (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Total Non-Current Liabilities data on record, last reported at -$2.0 billion in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 129.54% year-over-year to -$2.0 billion; the TTM value through Dec 2025 reached -$2.0 billion, down 129.54%, while the annual FY2025 figure was -$2.0 billion, 129.54% down from the prior year.
  • Total Non-Current Liabilities reached -$2.0 billion in Q4 2025 per REGN's latest filing, down from $7.3 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $7.3 billion in Q3 2025 and bottomed at -$29.7 billion in Q2 2024.
  • Average Total Non-Current Liabilities over 5 years is $426.1 million, with a median of $5.9 billion recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: soared 136.84% in 2022, then tumbled 600.93% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $5.8 billion in 2021, then grew by 2.81% to $5.9 billion in 2022, then increased by 5.76% to $6.3 billion in 2023, then grew by 9.3% to $6.8 billion in 2024, then tumbled by 129.54% to -$2.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were -$2.0 billion in Q4 2025, $7.3 billion in Q3 2025, and $6.6 billion in Q2 2025.